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Abstract 
Background: Severe aortic valve stenosis is one of the most common cause of mortality in adult patients affected 
with metabolic syndrome, a condition associated with an active inflammatory process involving also mast cells and 
their mediators, in particular tryptase. The aim of this study was to characterize the possible long-term prognostic role 
of tryptase in severe aortic valve stenosis.
Case presentation: The baseline serum tryptase was measured in 5 consecutive patients admitted to our Hospital 
to undergo aortic valve replacement for severe acquired stenosis. Within 2 years after, the patients were evaluated for 
the occurrence of major cardiovascular events (MACE). The tryptase measurements were higher in patients experienc-
ing MACE (10.9, 11.7 and 9.32 ng/ml) than in non-MACE ones (5.69 and 5.58 ng/ml).
Conclusions: In patients affected with severe aortic stenosis, baseline serum tryptase may predict occurence of 
MACE. Further studies are needed to demonstrate the long-term prognostic role of this biomarker.
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Background
Severe aortic valve stenosis is one of the most common 
cause of mortality in adult patients affected with meta-
bolic syndrome [1], i.e. a clinical condition characterized 
from visceral obesity that is traduced into insulin resist-
ance, atherogenic dyslipidemia and proinflammatory 
state [2]. It is frequently due to an active process involv-
ing several pathways, including lipid infiltration, chronic 
inflammation, fibrosis formation, osteoblasts activation, 
and valve mineralization. Other causes are congenital 
valve defects, systemic inflammatory diseases, and endo-
carditis [3]. Prevalence is between 2 and 9% in subjects 
over 65 years and it increases significantly in forthcom-
ing decades as a consequence of the ageing population 
and of more accurate diagnostic methods [4]. Severe aor-
tic stenosis is defined by the presence of maximum aor-
tic velocity ≥ 4 m/s, or aortic valve area ≤ 1.0 cm2, or by 
the presence of severe leaflet calcification and severely 
reduced leaflet opening. Surgical aortic valve replace-
ment is indicated in symptomatic patients with severe 
high-gradient aortic stenosis, and in asymptomatic ones 
with severe aortic stenosis and left ventricular ejec-
tion fraction < 50% [5]. Its natural history results in the 
obstruction of the left ventricular outflow, followed by 
pressure overload and compensatory hypertrophy of 
the left ventricle. Excessive hypertrophy may decrease 
coronary blood flow reserve, increase collagen synthe-
sis, interstitial fibrosis, and myocyte degeneration result-
ing in ischemic cardiac disease, sudden death and heart 
failure syndrome. Moreover, these patients have major 
risk of bleeding due to angiodysplasia, alterated plate-
lets function and low concentration of von Willebrand 
factor [3]. High-sensitivity cardiac troponin T (hsTnT) 
is usefulness for risk stratification of severity and mor-
tality [6]. However, recently some authors described the 
role of mast cells in calcified aortic stenosis [7] and an 
autoptic study detected these cells in the excised valves 
of patient undergoing elective aortic valve replacement in 
comparison with normal aortic valves from five healthy 
subjects obtained on autopsy served as negative controls 
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[8]. In light of the above, we studied basal serum tryptase 
as a new serological prognostic biomarker in aortic valve 
stenosis. Tryptase is a mast cell serine protease that pro-
vides information about mast cell number, distribution, 
and activation depending on the clinical context [9]. In 
some cardiovascular diseases, this enzyme has important 
implications and represents an index of mast cells’ bur-
den [10, 11]. In particular, in subjects affected with acute 
coronary syndrome we found higher basal tryptase val-
ues in so defined ‘cardiovascular complex’ patients than 
in ‘non-complex’ ones [12]. Moreover, in the same popu-
lation the basal serum tryptase was significantly corre-
lated to the development of major cardiovascular events’ 
(MACE) up to 2  years, demonstrating a possible long-
term prognostic role of this biomarker [13].
Cases report
Herein, we described a total of 5 consecutive patients 
admitted to our Hospital from January 2015 to Decem-
ber 2016, to undergo aortic valve replacement for severe 
acquired stenosis. None was affected with autoimmunity 
diseases, severe allergies, cancer, renal failure, mastocy-
tosis, refractory anemia, myelodysplastic syndromes, and 
hypereosinophilic syndrome. After admission, we col-
lected from all the patients medical history, echo-cardio-
gram, serum tryptase, C-reactive protein, hsTnT, plasma 
glucose, and lipid parameters. Serum tryptase levels 
were measured by ImmunoCAP tryptase in vitro fluoro-
enzyme-immunoassay test (Phadia, now Thermo Fisher 
Scientific, Uppsala, Sweden), according to the manufac-
turer’s instruction. Within 2  years after the aortic valve 
replacement, the patients were evaluated for the occur-
rence of MACE including myocardial infarction, cardiac 
arrhythmias, stroke, systemic embolism, heart failure 
and sudden death. Table 1 shows patients’ clinical char-
acteristics. At 2-year follow up, 3 patients experienced 
MACE: 1 died and 2 had acute coronary syndrome. In 
these patients tryptase levels were 10.9, 11.7 and 9.32 ng/
ml respectively, about twofold higher than in non-MACE 
ones: 5.69 and 5.58 ng/ml.
Conclusions
Our results could be in agreement with the literature of 
the last few decades, in which a relationship between 
high tryptase levels and the development of MACE in 
acute coronary syndrome patients was found, to demon-
strate the tryptase role as a marker of the inflammatory 
and atherosclerotic process [13, 14]. Indeed, in stenotic 
aortic valves mast cells secrete tryptase, chymase, cath-
epsin G and vascular endothelial growth factor inducing 
extracellular matrix degradation and valvular neovascu-
larization [15].
Table 1 Clinical characteristics of study patients
STEACS ST elevation acute coronary syndrome, COPD Chronic obstructive pulmonary disease, CRP C-reactive protein, hsTnT high-sensitivity cardiac troponin T, HDL 
high-density lipoprotein, LDL low-density lipoprotein, MACE major cardiovascular events
Sex/age, years MACE-patients Non-MACE patients
M/85 F/58 F/53 F/72 F/77
Clinical history
 Hypertension Yes Yes Yes Yes Yes
 Hypercolesterolemia No Yes No Yes Yes
 Currently smoking Yes No No No No
 Diabetes mellitus No Yes No No No
 Obesity No No No No Yes
 COPD Yes No No No No
Left ventricle ejection fraction during index hospitalization
 Ejection fraction (%) 30 58 56 40 60
 Mean transvalvular gradient (mmHg) 70 75 70 65 65
Diagnostic findings
 Tryptase, ng/ml 10.9 11.7 9.32 5.69 5.58
 CRP, mg/dl 3.2 0.8 0.2 0.3 1.1
 hsTnT, ng/l 49.5 8.0 7.9 40 7.2
 Serum triglycerides, mg/dl 117 189 150 176 68
 HDL cholesterol, mg/dl 32 40 38 37 72
 LDL cholesterol, mg/dl 90 97 100 116 89
 Plasma glucose, mg/dl 119 181 104 87 114
Major cardiovascular events Sudden death STEACS STEACS None None
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In conclusion, we hypothesized that high tryptase 
levels may be a risk factor of development of MACE in 
severe aortic stenosis. Further studies on largest popula-
tions are required to confirm this hypothesis.
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